The FDA recently approved a bioengineered blood vessel, which becomes part of a patient’s body over time. It’s designed to ...

Trusted for more than 20 years, HEMASHIELD grafts are the most used, most studied vascular products available in the market today. More than 2 million HEMASHIELD grafts have been implanted ...

LifeSpan ePTFE Vascular Grafts for peripheral vascular reconstructions and AV Access have been used in clinical practice for more than 15 years. It features soft ePTFE material with superb suture ...

Plans for filing an IND was agreed with the FDA in a recent meeting –– Positive preclinical results of the small-diameter ATEV were recently ...

Looking for remote jobs that will allow you to travel the world or work from home? FlexJobs has issued a new report with the 30 best companies for remote work. Time Out has just released its 2025 ...

DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology company valued at $567 million, has announced its intention to file an Investigational New Drug (IND) application with the U.S. Food and ...

Cite this: Technology Insight: The Evolution of Tissue-Engineered Vascular Grafts--From Research to Clinical Practice - Medscape - Jul 01, 2007. The recent transition to clinical use by two ...

Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...

To date only the 6.0mm configuration of the ATEV has been studied in human trials, specifically in studies conducted in vascular trauma ... for Humacyte,” said Laura Niklason, M.D., Ph.D ...